• Divested MatTek & Visikol to Sartorius for $80M, strengthening balance sheet
• Macroeconomic headwinds persist: NIH funding cuts, tariff turbulence delaying CapEx
• Life Science Solutions: mixed results; SCIENION showed healthy growth & profitability
• Lab Automation: high demand but fewer project starts and delays; leadership & process changes underway at Biosero
Q2 2025 (y/y)
• Net sales: SEK 324.2M (−23.4%)
• Organic growth: −17.0%
• Gross margin: 43.9% (↓ from 52.3%)
• Adj. EBITDA: SEK −48.8M (−15.1% margin)
• Net loss: SEK −181.7M (−2.55/share)
H1 2025 (y/y)
• Net sales: SEK 659.0M (−21.8%)
• Organic growth: −19.4%
• Gross margin: 50.4% (↑ from 49.1%)
• Adj. EBITDA: SEK −69.0M (−10.5% margin)
• Net loss: SEK −417.1M (−5.87/share)
• Operating cash flow: SEK +48.4M (vs −68.2M)
Post Q2 Events
• Completed MatTek & Visikol divestment; net proceeds $77.2M
• Repurchased SEK 98M convertible bonds